ClinicalTrials.gg
Not yet recruitingNCT07857629BPT-CBT-DUpdated Oct 5, 2026

Brief Psychoanalytic Therapy Versus Cognitive Behavioral Therapy for Major Depressive Disorder

An interventional study of Brief Psychoanalytic Therapy and Cognitive Behavioral Therapy in Major Depressive Disorder (MDD, sponsored by Istanbul Nisantasi University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Istanbul Nisantasi University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.

Planned enrollment
13th of 24
90 · median 95
Started
2026
with 6 others
No phase
11 of 32
6 open now
Primary completion
2027-08
later than 12 of 14 live
Registered
30th of 32
by date
Lead sponsor
1 of 32
Istanbul Nisantasi University

Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is the 13th largest by planned enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2026, is one of 11 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 30th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Depressive Disorder, Major with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether brief psychoanalytic therapy and cognitive behavioral therapy (CBT) reduce depressive symptoms in adults aged 18 to 65 who have been diagnosed with major depressive disorder. The main questions it aims to answer are:

  • Does brief psychoanalytic therapy reduce depression severity more than a waitlist control condition after 18 weeks?
  • Does CBT reduce depression severity more than a waitlist control condition after 18 weeks?

Researchers will also compare brief psychoanalytic therapy with CBT to explore whether one works better than the other, and will examine whether changes in defense mechanisms and automatic negative thoughts explain improvement in each therapy.

Participants will:

  • Be randomly assigned to brief psychoanalytic therapy, CBT, or a waitlist control group (30 participants per group)
  • In the therapy groups, attend 18 weekly individual therapy sessions of 50 minutes each
  • In the waitlist group, continue their usual psychiatric care without psychotherapy for 18 weeks, and then be offered one of the therapies
  • Complete clinical interviews and questionnaires about depression, anxiety, quality of life, thought patterns and coping styles before treatment, at week 9 and at week 18
  • In the therapy groups, complete follow-up assessments 6 and 12 months after treatment ends
Read the detailed description

Background and rationale Major depressive disorder is a leading cause of disability worldwide. Cognitive behavioral therapy (CBT) is the most extensively studied psychotherapy for depression, and short-term psychodynamic/psychoanalytic therapies have also shown efficacy in randomized trials. Direct comparisons of the two approaches remain limited, particularly in Türkiye, and few trials have examined whether each therapy works through its theoretically proposed mechanism.

Design Single-site, three-arm, parallel-group, randomized controlled trial with assessor-blinded outcome evaluation. Ninety adults with a DSM-5-TR diagnosis of major depressive disorder will be randomized in a 1:1:1 ratio to brief psychoanalytic therapy (BPT), CBT, or waitlist plus treatment as usual (WL-TAU).

Randomization and allocation concealment A computer-generated sequence with permuted blocks of 3 and 6 will be prepared by a researcher not involved in recruitment, assessment or treatment. Randomization will be stratified by current antidepressant use (yes/no) and baseline severity (HAM-D-17 14-18 vs. 19 or higher). Allocation will be concealed in sequentially numbered, sealed, opaque envelopes opened only after baseline assessment.

Blinding Clinician-rated outcomes (HAM-D-17) will be obtained by an independent assessor blind to group allocation. Participants will be instructed not to disclose their allocation. At week 18, the assessor will record a guess of each participant's group to evaluate blinding integrity. Participants and therapists cannot be blinded.

Interventions Brief psychoanalytic therapy: 18 weekly individual sessions of 50 minutes, manualized according to Luborsky's supportive-expressive model and the unified protocol for short-term psychodynamic therapy of depression (Leichsenring \& Schauenburg, 2014). Phases: alliance building and formulation of a focal Core Conflictual Relationship Theme (sessions 1-4); working through the focal conflict, defenses, self-criticism, loss and aggression, including here-and-now relational patterns (sessions 5-14); termination phase focusing on separation and loss (sessions 15-18).

CBT: 18 weekly individual sessions of 50 minutes based on Beck's cognitive therapy for depression. Phases: psychoeducation and behavioral activation (sessions 1-4); identification and restructuring of automatic thoughts (sessions 5-12); modification of intermediate and core beliefs (sessions 13-16); relapse prevention (sessions 17-18). Structured homework is assigned each session.

Waitlist plus treatment as usual: participants continue routine psychiatric follow-up with antidepressant doses held stable and receive no psychotherapy for 18 weeks. Brief non-therapeutic safety check-in calls are made every 4 weeks. After the week-18 assessment, participants are offered either active therapy.

In all arms, participants taking antidepressants must have been on a stable dose for at least 8 weeks before enrollment and agree to keep the dose unchanged during the 18-week treatment phase. Sessions may be completed within a window of up to 20 weeks to accommodate missed appointments.

Therapists and treatment fidelity Each arm will be delivered by separate licensed clinical psychologists trained in the respective modality, with weekly supervision. All sessions will be audio-recorded with consent. A random 20% of sessions will be rated for adherence using the Comparative Psychotherapy Process Scale (psychodynamic-interpersonal and cognitive-behavioral subscales), and CBT sessions additionally with the Revised Cognitive Therapy Scale (CTS-R).

Assessments Diagnosis will be established by a psychiatrist and confirmed with the Structured Clinical Interview for DSM-5, Clinician Version (SCID-5-CV). Outcomes will be assessed at baseline, week 9 and week 18 in all arms, and at 6- and 12-month follow-up in the two active arms. All instruments are used in their validated Turkish versions: Hamilton Depression Rating Scale (HAM-D-17), Beck Depression Inventory-II, Beck Anxiety Inventory, WHOQOL-BREF-TR, Automatic Thoughts Questionnaire, Defense Style Questionnaire-40, and Working Alliance Inventory (active arms, sessions 3 and 12).

Safety monitoring Suicidal ideation will be monitored at every assessment (HAM-D item 3, BDI-II item 9) and weekly by therapists. Participants in any arm showing clinically significant deterioration (an increase of 25% or more in HAM-D-17 from baseline) or emergent suicide risk (HAM-D item 3 score of 3 or higher) will be referred immediately for appropriate clinical care. These participants will remain in the intention-to-treat analysis. Adverse events will be recorded throughout.

Sample size With 30 participants per arm, the study has 80% power (two-tailed alpha = .05) to detect a between-group effect of d = 0.80 for each active therapy versus waitlist, allowing for approximately 15% attrition. The study is not powered for equivalence or non-inferiority testing between the two active therapies; this comparison is exploratory.

Statistical analysis Primary analyses will follow the intention-to-treat principle using linear mixed-effects models with group, time and group-by-time interaction as fixed effects, baseline HAM-D-17 as a covariate, and restricted maximum likelihood estimation for missing data. The two primary contrasts (BPT vs. WL-TAU; CBT vs. WL-TAU) will be adjusted with the Holm procedure. Response (reduction of 50% or more in HAM-D-17) and remission (HAM-D-17 of 7 or less) will be analyzed with logistic regression. Mediation analyses will test whether change in defense style (DSQ-40) and automatic thoughts (ATQ) mediates outcomes in BPT and CBT, respectively. A per-protocol analysis (at least 12 sessions attended) will serve as a sensitivity analysis.

03

Conditions studied

  • Major Depressive Disorder (MDD

Keywords

  • Psychodynamic Psychotherapy
  • Short-Term Psychoanalytic Therapy
  • Supportive-Expressive Therapy
  • Cognitive Behavioral Therapy
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of Major Depressive Disorder (single or recurrent episode), established by a psychiatrist and confirmed with the Structured Clinical Interview for DSM-5, Clinician Version (SCID-5-CV)
  • Hamilton Depression Rating Scale (HAM-D-17) total score of 14 or higher at baseline
  • Either not taking antidepressant medication, or on a stable antidepressant dose for at least 8 weeks before enrollment and willing to keep the dose unchanged during the 18-week treatment phase
  • Literate in Turkish and able to attend weekly sessions
  • Written

Exclusion criteria

Exclusion Criteria:

  • Bipolar disorder, schizophrenia spectrum or other psychotic disorder, or major depressive disorder with psychotic features
  • Moderate or severe substance use disorder within the past 6 months
  • High suicide risk, defined as active suicidal ideation with plan or intent, or a suicide attempt within the past 12 months
  • Another primary psychiatric diagnosis requiring different treatment (e.g., posttraumatic stress disorder, obsessive-compulsive disorder, eating disorder, or severe personality disorder)
  • Neurological disorder, dementia, intellectual disability, or a medical condition that could explain the depressive symptoms (e.g., untreated hypothyroidism)
  • Currently receiving any psychotherapy, or having received cognitive behavioral or psychodynamic therapy within the past 12 months
  • Electroconvulsive therapy or repetitive transcranial magnetic stimulation within the past 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Brief Psychoanalytic Therapy

    Participants receive 18 weekly individual 50-minute sessions of manualized brief psychoanalytic therapy over 18 weeks. Participants on antidepressants continue a stable dose.

    Behavioral: Brief Psychoanalytic Therapy

  • Experimental
    Cognitive Behavioral Therapy

    Participants receive 18 weekly individual 50-minute sessions of manualized cognitive behavioral therapy over 18 weeks. Participants on antidepressants continue a stable dose.

    Behavioral: Cognitive Behavioral Therapy

  • No intervention
    Waitlist Plus Treatment as Usual

    Participants continue routine psychiatric follow-up with antidepressant doses held stable and receive no psychotherapy for 18 weeks. Brief non-therapeutic safety check-in calls are made every 4 weeks. After the week-18 assessment, participants are offered either brief psychoanalytic therapy or cognitive behavioral therapy.

Interventions

  • BehavioralBrief Psychoanalytic Therapy

    Manualized brief psychoanalytic therapy based on Luborsky's supportive-expressive model and the unified protocol for short-term psychodynamic therapy of depression. Delivered as 18 weekly individual 50-minute sessions by licensed clinical psychologists trained in psychodynamic therapy. Focuses on a Core Conflictual Relationship Theme, defenses, self-criticism, loss and aggression, and includes a structured termination phase addressing separation and loss.

  • BehavioralCognitive Behavioral Therapy

    Manualized cognitive behavioral therapy based on Beck's cognitive therapy for depression. Delivered as 18 weekly individual 50-minute sessions by licensed clinical psychologists trained in CBT. Includes psychoeducation, behavioral activation, cognitive restructuring of automatic thoughts, modification of intermediate and core beliefs, relapse prevention, and structured weekly homework.

06

What researchers measure

Primary outcomes

  1. Change in Depression Severity (HAM-D-17)

    Depression severity measured with the 17-item Hamilton Depression Rating Scale (Turkish version), administered by an independent assessor blind to group allocation. Total score ranges from 0 to 52; higher scores indicate more severe depression. Change from baseline to week 18 is compared between each active therapy and the waitlist control.

    Time frame: Baseline, week 9, and week 18

Secondary outcomes

  1. Change in Self-Reported Depressive Symptoms (BDI-II)

    Measured with the Beck Depression Inventory-II (Turkish version). Total score ranges from 0 to 63; higher scores indicate more severe depressive symptoms.

    Time frame: Baseline, week 9, and week 18

  2. Treatment Response Rate

    Percentage of participants achieving a reduction of 50% or more in HAM-D-17 total score from baseline.

    Time frame: Week 18

  3. Remission Rate

    Percentage of participants with a HAM-D-17 total score of 7 or less.

    Time frame: Week 18

  4. Change in Anxiety Symptoms (BAI)

    Measured with the Beck Anxiety Inventory (Turkish version). Total score ranges from 0 to 63; higher scores indicate more severe anxiety.

    Time frame: Baseline, week 9, and week 18

  5. Change in Quality of Life (WHOQOL-BREF-TR)

    Measured with the Turkish version of the World Health Organization Quality of Life Scale, Brief Form. Physical, psychological, social relationships, and environment domain scores are transformed to a 0-100 scale; higher scores indicate better quality of life.

    Time frame: Baseline and week 18

  6. Change in Negative Automatic Thoughts (ATQ)

    Measured with the Automatic Thoughts Questionnaire (Turkish version), 30 items. Total score ranges from 30 to 150; higher scores indicate more frequent negative automatic thoughts. Examined as a proposed mediator of change in cognitive behavioral therapy.

    Time frame: Baseline, week 9, and week 18

  7. Change in Defense Styles (DSQ-40)

    Measured with the Defense Style Questionnaire-40 (Turkish version). Mean scores for mature, neurotic, and immature defense styles each range from 1 to 9; higher scores indicate greater use of that defense style. Examined as a proposed mediator of change in brief psychoanalytic therapy.

    Time frame: Baseline, week 9, and week 18

  8. Therapeutic Working Alliance (WAI)

    Measured in the two active therapy arms with the short form of the Working Alliance Inventory (Turkish version), administered after therapy sessions 3 and 12. Covers goal, task, and bond dimensions. Total score ranges from 12 to 84; higher scores indicate a stronger therapeutic alliance.

    Time frame: Week 3 and week 12

  9. Maintenance of Treatment Effects at Follow-Up

    Depression severity (HAM-D-17, range 0-52; BDI-II, range 0-63; higher scores indicate greater severity) in the brief psychoanalytic therapy and cognitive behavioral therapy arms, compared with post-treatment scores to assess durability of change.

    Time frame: 6 months and 12 months after the end of treatment (approximately week 44 and week 70 from baseline)

  10. Treatment Dropout and Session Attendance

    Percentage of participants discontinuing treatment before session 12, and mean number of sessions attended per arm.

    Time frame: Up to 20 weeks

  11. Number of Participants With Adverse Events or Clinical Deterioration

    Number of participants with adverse events, clinically significant deterioration (increase of 25% or more in HAM-D-17 from baseline), or emergent suicide risk (HAM-D item 3 score of 3 or higher) requiring referral.

    Time frame: Up to 20 weeks

07

Study locations

1 site
  • Istanbul Nisantasi Universitesi
    Istanbul, Istanbul 34320, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results (baseline characteristics and all primary and secondary outcome measures) will be made available to qualified researchers upon reasonable request to the principal investigator.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months after publication of the primary results and ending 5 years after publication.

Access criteria: Requests must include a methodologically sound proposal and be directed to the principal investigator (metincinaroglu@gmail.com). Data will be shared after approval of the proposal and signing of a data use agreement, in accordance with Turkish personal data protection law (KVKK) and the approving ethics committee's requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 9 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 5, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857629
Lead sponsor
Istanbul Nisantasi University
Collaborators
Halic University, Uskudar University
Responsible party
Metin Çınaroğlu (Assistant Professor of Psychology, Istanbul Nisantasi University) — Principal investigator
First posted
Oct 5, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Metin Çınaroğlu, Phd
Contact
metincinaroglu@gmail.com
09053247320
Eda Yılmazer, Phd
Contact
laledayilmazer@gmail.com
+905322575880
Metin Çınaroğlu
study chair · Istanbul Nisantasi Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion